N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide Chemical Properties

Melting point:

221℃

Density 

1.46

storage temp. 

-20C

solubility 

DMSO:5.0(Max Conc. mg/mL);10.65(Max Conc. mM)

form 

Yellow solid

pka

11.19±0.70(Predicted)

color 

Light yellow to yellow

N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide Usage And Synthesis

General Description

A cell-permeable quinolinecarboxamide compound that is shown to inhibit the mitochondrial SIRT3 in a substrate AceCS2-competitive (K_i = 0.56 μM; K_m = 2.44 μM), but NAD⁺-uncompetitive (K_i = 0.34 μM; K_m = 280 μM), manner. Also reported to decrease cellular p53 Lys382 acetylation (Effective conc. = 10 μM in U2OS and MEF cultures) and inhibit p300 HAT activity (IC₅₀ = 9 μM) in vitro, as well as offer therapeutic benefits in several murine and rodent type 2 diabetes models (100 mg/kg/dayl p.o.) in vivo. Whether and how SRT1720 activates SIRT1 activity remains uncertain. Also available as a 25 mM solution in DMSO (Cat. No. 530748).

storage

Store at -20°C

N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide(925434-55-5)Related Product Information

• 2-Chloro-N-(6-methoxy-4-quinolinyl)-5-nitrobenzamide
• 4-Quinolinecarboxamide, N-[3-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl]phenyl]-1,2-dihydro-2-oxo-
• NA
• SR-717
• SR9009
• SR8278
• SR19881
• SR-9243
• SRPK inhibitor
• SR 1078
• SRI 31215
• SR 0987
• SR27897
• SR17018
• N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-2-morpholino-9H-purin-6-amine
• SRT3025
• SRT2104 (GSK2245840)
• SR-4835